| 10.56 -0.52 (-4.69%) | 09-08 10:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.54 | 1-year : | 15.82 |
| Resists | First : | 11.6 | Second : | 13.54 |
| Pivot price | 10.81 |
|||
| Supports | First : | 9.98  |
Second : | 8.98 |
| MAs | MA(5) : | 11.14 |
MA(20) : | 10.61 |
| MA(100) : | 9.57 |
MA(250) : | 10.1 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 68.4 |
D(3) : | 82.5 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 20.55 | Low : | 7.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRBP ] has closed above bottom band by 32.4%. Bollinger Bands are 2.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.46 - 11.52 | 11.52 - 11.57 |
| Low: | 10.89 - 10.97 | 10.97 - 11.03 |
| Close: | 10.96 - 11.08 | 11.08 - 11.18 |
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Fri, 04 Sep 2026
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Fri, 04 Sep 2026
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Wed, 02 Sep 2026
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Fri, 21 Aug 2026
Corbus Pharmaceuticals Holdings, Inc. Revenue Breakdown – NASDAQ:CRBP - TradingView
Tue, 18 Aug 2026
Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans? - simplywall.st
Thu, 06 Aug 2026
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 73.8 (%) |
| Shares Short | 2,150 (K) |
| Shares Short P.Month | 2,100 (K) |
| EPS | -6.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53 % |
| Return on Equity (ttm) | -95.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.67 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -1.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|